Weinstein Robert's Form 4/A amendment
AmendedPharmaCyte Biotech, Inc. (PMCB) · filed Jul 17, 2026
- Accession no.
- 0001683168-26-005619
- Filed
- Jul 17, 2026, 5:00 PM ET
- Trade date
- Mar 31, 2026
- Filing delay
- 108 days
- Rule 10b5-1 plan
- Not checked
- Original filed
- Apr 2, 2026
This filing lists 0 non-derivative transactions and 1 derivative transaction. It was filed 108 days after the trade.
This amendment replaces 0001683168-26-002633 (filed Apr 2, 2026).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Weinstein RobertCIK 0001213709 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
This filing has no transactions of this kind.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | Stock Option (Right to Buy) | JOtherAcquired | 0 | – | – | 0 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.